In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002

Samuel K Bouchillon; Daryl J Hoban; Brian M Johnson; Tim M Stevens; Michael J Dowzicky; David H Wu; Patricia A Bradford

doi:10.1016/j.diagmicrobio.2004.11.006

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002

Diagn Microbiol Infect Dis. 2005 Apr;51(4):291-5. doi: 10.1016/j.diagmicrobio.2004.11.006.

Authors

Samuel K Bouchillon¹, Daryl J Hoban, Brian M Johnson, Tim M Stevens, Michael J Dowzicky, David H Wu, Patricia A Bradford

Affiliation

¹ Laboratories International for Microbiology Studies, Schaumburg, IL 60179, USA. sbouchillon@ihmainc.com

PMID: 15808321
DOI: 10.1016/j.diagmicrobio.2004.11.006

Abstract

Tigecycline is the first glycylcycline antimicrobial in phase III clinical trials. This study compares the in vitro activity of tigecycline to 12 other predominately broad-spectrum antimicrobials against 3049 recent inpatient isolates from 38 clinical centers in 17 countries. The minimum concentration at which tigecycline inhibited 90% of the isolates for the entire collection, excluding Pseudomonas aeruginosa, was 1 microg/mL, including vancomycin-resistant enterococci-, extended-spectrum beta-lactamase-, and methicillin-resistant Staphylococcus aureus-resistant phenotypes.

Publication types

Comparative Study
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Drug Resistance, Bacterial
Europe
Gram-Negative Bacteria / drug effects*
Gram-Negative Bacteria / isolation & purification
Gram-Negative Bacterial Infections / microbiology
Gram-Positive Bacteria / drug effects*
Gram-Positive Bacteria / isolation & purification
Gram-Positive Bacterial Infections / microbiology
Humans
Microbial Sensitivity Tests / methods
Middle East
Minocycline / analogs & derivatives*
Minocycline / pharmacology*
South Africa
Tigecycline

Substances

Anti-Bacterial Agents
Tigecycline
Minocycline